Berra Yazar-Klosinski
Berra Yazar-Klosinski
Chief Development Officer
Dr. Berra Yazar-Klosinski is Chief Development Officer at Freedom Biosciences, where she leads clinical development, regulatory strategy, and translational research across the company’s pipeline of neuropsychiatric therapeutics.
She is a drug development leader with deep expertise in advancing novel neuropsychiatric treatments through late-stage CNS clinical trials and Breakthrough-designated regulatory pathways. She is best known for her leadership of the MDMA-assisted therapy program for post-traumatic stress disorder (PTSD), including pivotal Phase 3 trials demonstrating durable efficacy and safety, and contributing to the establishment of a regulatory framework for psychedelic therapies. She has led the preparation of the first New Drug Application (NDA) for a psychedelic therapy, working closely with the U.S. Food and Drug Administration and global regulatory agencies including MHRA, EMA, and Health Canada. Prior to joining Freedom, she founded Yazar Lab and previously served as Chief Scientific Officer at Lykos Therapeutics.
